Abstract
The purpose of this review article is to examine the various studies that have evaluated microspheres for delivery of antimycobacterial drugs. Some of the studies strictly involve the development and evaluation of microspheres for use in antimycobacterial drug delivery, whereas others actually use drug-loaded microspheres to treat mycobacterial infections in cell lines and small animals. Although there is a potential to use microspheres to treat a variety of mycobacterial infections, it appears that most of the studies so far have focused on the etiological agent of tuberculosis, Mycobacterium tuberculosis. As a result, the infectious studies presented here all entail the treatment of that mycobacterial agent. This review will address the following aspects that are important if microspheres are to be considered an acceptable therapeutic tool: 1) in vitro release characteristics, 2) delivery, release and efficacy in macrophages, 3) effectiveness in infected small animal models, 4) safe and combined use with other antimycobacterial agents, and 5) reduced toxicity. It is hoped that once all of these parameters are evaluated, a conclusion regarding the benefit of microsphere technology in the treatment of mycobacterial diseases can be reached.
Keywords: mycobacterial infections, tuberculosis, microparticles, microspheres
Current Pharmaceutical Design
Title: Microsphere Technology for Chemotherapy of Mycobacterial Infections
Volume: 10 Issue: 26
Author(s): William W. Barrow
Affiliation:
Keywords: mycobacterial infections, tuberculosis, microparticles, microspheres
Abstract: The purpose of this review article is to examine the various studies that have evaluated microspheres for delivery of antimycobacterial drugs. Some of the studies strictly involve the development and evaluation of microspheres for use in antimycobacterial drug delivery, whereas others actually use drug-loaded microspheres to treat mycobacterial infections in cell lines and small animals. Although there is a potential to use microspheres to treat a variety of mycobacterial infections, it appears that most of the studies so far have focused on the etiological agent of tuberculosis, Mycobacterium tuberculosis. As a result, the infectious studies presented here all entail the treatment of that mycobacterial agent. This review will address the following aspects that are important if microspheres are to be considered an acceptable therapeutic tool: 1) in vitro release characteristics, 2) delivery, release and efficacy in macrophages, 3) effectiveness in infected small animal models, 4) safe and combined use with other antimycobacterial agents, and 5) reduced toxicity. It is hoped that once all of these parameters are evaluated, a conclusion regarding the benefit of microsphere technology in the treatment of mycobacterial diseases can be reached.
Export Options
About this article
Cite this article as:
Barrow W. William, Microsphere Technology for Chemotherapy of Mycobacterial Infections, Current Pharmaceutical Design 2004; 10 (26) . https://dx.doi.org/10.2174/1381612043383197
DOI https://dx.doi.org/10.2174/1381612043383197 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Caveats Regarding the Use of IL-10 and IL-10 Antagonist as Immunotherapeutic Factors
Letters in Drug Design & Discovery Recent Advances Using Phosphodiesterase 4 (PDE4) Inhibitors to Treat Inflammatory Disorders: Animal and Clinical Studies
Current Drug Therapy Isoniazid Induced Convulsions at Therapeutic Dose in an Alcoholic and Smoker Patient
Current Drug Safety Biosurfactants as a Novel Additive in Pharmaceutical Formulations: Current Trends and Future Implications
Current Drug Metabolism Molecular Targets for Design of Novel Inhibitors to Circumvent Aminoglycoside Resistance
Current Drug Targets Artificial Neural Network Analysis of Pharmacokinetic and Toxicity Properties of Lead Molecules for Dengue Fever, Tuberculosis and Malaria
Current Computer-Aided Drug Design New Tuberculosis Drugs in Development
Current Topics in Medicinal Chemistry Label-Free Mass Spectrometry-Based Plasma Proteomics Identified LY6D, DSC3, CDSN, SERPINB12, and SLURP1 as Novel Protein Biomarkers For Pulmonary Tuberculosis
Current Proteomics Autoimmune Diseases in Gastroenterology
Current Pharmaceutical Design Targeting Bacterial Metalloenzymes: A New Strategy for the Development of Anti-Infective Agents
Anti-Infective Agents in Medicinal Chemistry Vitamins B1, B2, B3 and B9 – Occurrence, Biosynthesis Pathways and Functions in Human Nutrition
Mini-Reviews in Medicinal Chemistry An Overview on Pyranocoumarins: Synthesis and Biological Activities
Current Organic Chemistry Editorial [Towards an Ecology of Collective Innovation: Human Variome Project (HVP), Rare Disease Consortium for Autosomal Loci (RaDiCAL) and Data-Enabled Life Sciences Alliance (DELSA)]
Current Pharmacogenomics and Personalized Medicine Key Amino Acids of Arabidopsis VKOR in the Activity of Phylloquinone Reduction and Disulfide Bond Formation
Protein & Peptide Letters Targeting Pattern Recognition Receptors (PRRs) in Nano- Adjuvants: Current Perspectives
Current Bionanotechnology (Discontinued) Rifampicin Induced Aggregation of Ovalbumin: Malicious Behaviour of Antibiotics
Protein & Peptide Letters Targeting the Human Thioredoxin System by Diverse Strategies to Treat Cancer and Other Pathologies
Recent Patents on DNA & Gene Sequences MiR-147: Functions and Implications in Inflammation and Diseases
MicroRNA Advances in Metabonomics on Infectious Diseases
Current Metabolomics Laccase Regulators in Anti-fungal Drug Discovery: Dark Lessons from the AIDS-related Pathogen, Cryptococcus
Current Enzyme Inhibition